Diagnosis, prognosis and therapeutic control of malignant diseases using PLA2R1 methylation analysis
The invention relates to the field of medicine, specifically to the diagnostics, prognosis and therapy control of tumour diseases. The invention is based on the hitherto unknown epigenetic silencing, discovered by chance by the inventors, of the phospholipase-A2-receptor-1-coding gene in leukaemia cells and in patients suffering from leukaemias and solid tumours. Based on this finding, the invention provides methods and a kit with which the degree of methylation of the phospholipase-A2-receptor-1 gene in an isolated sample of the patient is determined.
Property right: DE102010031354B3; WO002012007462A1
Further Information: PDF
GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120
Contact
Beate-Victoria Ermisch
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Largest magnetic anisotropy of a molecule measured at BESSY II
At the Berlin synchrotron radiation source BESSY II, the largest magnetic anisotropy of a single molecule ever measured experimentally has been determined. The larger this anisotropy is, the better a…
Breaking boundaries: Researchers isolate quantum coherence in classical light systems
LSU quantum researchers uncover hidden quantum behaviors within classical light, which could make quantum technologies robust. Understanding the boundary between classical and quantum physics has long been a central question…
MRI-first strategy for prostate cancer detection proves to be safe
Active monitoring is a sufficiently safe option when prostate MRI findings are negative. There are several strategies for the early detection of prostate cancer. The first step is often a…